Like I've always said - PRR needs to prove up sales.
(up to) 24 months in this market is a long time to wait for final enrollment and like it or not PRR is not the only player in the oncology market
Strong sales into a (possible) FDA approval will give you the MC you are talking about (although the 3 bucks a share some are quotingt is a MC equivalent to the entire globe's ovarian cancer therapeutics market)
pr out!! first patient, page-12
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2683 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 320760 | 2 |
View Market Depth
| Last trade - 09.43am 08/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
Day chart unavailable